Imprimis Pharmaceuticals has announced the acquisition of what it says are the largest compounding pharmacies for sinus drugs in the US: Topical Apothecary Group, LLC (doing business as TAG Pharmacy), Aerosol Science Laboratories, Inc. (ASL Pharmacy), and SinuTopic, Inc. (Sinus Dynamics Pharmacy). Websites for all three are nearly identical, offering compounding of … [Read more...] about Imprimis Pharmaceuticals acquires intranasal formulation compounding pharmacies
News
Zephex propellant production facility celebrates 20th anniversary
Mexichem's Zephex HFA medical propellant manufacturing facility in Cheshire UK has celebrated its 20th anniversary, the company announced. The Cheshire cGMP facility, which opened in 1995, is audited by both the FDA and MHRA. According to Mexichem, 80% of metered dose inhalers worldwide currently use propellants, and over the past 20 years, Zephex propellants have … [Read more...] about Zephex propellant production facility celebrates 20th anniversary
Hovione acquires new formulation facility in Portugal
Hovione has acquired a formulation facility located next to its existing Loures, Portugal facility for process chemistry and particle engineering, the company said. The new facility will be able to produce clinical trial supplies and commercial batches for both oral and inhalation drug products, including highly potent APIs. Hovione VP of R&D Filipe Gaspar … [Read more...] about Hovione acquires new formulation facility in Portugal
Phase 2 trial of Verona’s RPL554 for the treatment of COPD gets underway
The first patients have been dosed in a Phase 2a study of Verona Pharma's RPL554 inhaled PDE3/PDE4 inhibitor as an addition to albuterol (salbutamol) and with ipratropium for the treatment of COPD, Verona said. The double-blind, placebo-controlled, six way crossover study will enroll up to 30 patients and will use the new suspension formulation of RPL554. Verona … [Read more...] about Phase 2 trial of Verona’s RPL554 for the treatment of COPD gets underway
Impel NeuroPharma gets investment from 3M New Ventures
Impel NeuroPharma has announced that 3M New Ventures (3M NV) led the investment in its $12 million Series B financing round to raise money for commercialization of Impel's Precision Olfactory Delivery (POD) platform. Impel recently announced a partnership with 3M Drug Delivery Systems for development and commercialization of the intranasal technology. Impel CEO … [Read more...] about Impel NeuroPharma gets investment from 3M New Ventures
Ferrer affirms commitment to Adasuve
Grupo Ferrer, which is partnered with Alexza Pharmaceuticals on Adasuve Staccato loxapine inhalation powder in the EU, Latin America, CIS nations, Middle East, North Africa, and parts of Asia, has reiterated its support for the product. Alexza announced in June 2015 that it would stop manufacturing Adasuve for its partners and in September said that it was considering … [Read more...] about Ferrer affirms commitment to Adasuve
Kristine Senft appointed VP Sales & Marketing at Hovione
Hovione has announced that Kristine Senft has joined the company as VP, Sales and Marketing and will succeed Dave Hoffman as VP, Sales and Business Development upon his retirement in April 2016. Senft, who was most recently VP, Regenerative Materials at DSM Biomedical, will be based in New Jersey, where Hovione recently announced that it would be doubling the size of … [Read more...] about Kristine Senft appointed VP Sales & Marketing at Hovione
Lilly acquires Locemia’s intranasal glucagon powder
Eli Lilly has acquired worldwide rights to Locemia Solution's intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed. Lilly Diabetes President Enrique … [Read more...] about Lilly acquires Locemia’s intranasal glucagon powder
OptiNose raises up to $30 million for development of intranasal fluticasone
OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products. The company had announced completion of its previous round of financing in August 2014. According to the company, Phase 3 development of … [Read more...] about OptiNose raises up to $30 million for development of intranasal fluticasone
InCarda gets patents for inhaled cardiovascular therapies
InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company's inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary … [Read more...] about InCarda gets patents for inhaled cardiovascular therapies